Key facts
- It has raised $500K; the latest was Seed Round in Mar 2026.
- Notable investors include Y Combinator, Pioneer Fund, Lombardstreet Ventures, Scale Asia Ventures, ZAKA VC — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for CellType
- ·The full record, as it builds
Funding rounds
No funding rounds for CellType are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About CellType
Developer of a biological reasoning engine designed to simulate drug responses in human biology. The company trains large language models on cellular profiles to predict human-specific toxicity, discover biomarkers, and evaluate efficacy before clinical trials, enabling biotechnology and pharmaceutical organizations to de-risk target selection, optimize clinical trial design, and accelerate the discovery of novel therapeutics.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2025
- Employees
- 2
- Website
- celltype.com/
- Ownership
- Privately Held (backing)
CellType doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in CellType shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on CellType in its N-PORT filings yet. We sweep new filings monthly.